


## JAK2 JH2 Tracer

<b>Cat. No.:</b>	HY-102055
<b>CAS No.:</b>	2101955-00-2
<b>Molecular Formula:</b>	C <sub>38</sub> H <sub>27</sub> F <sub>2</sub> N <sub>7</sub> O <sub>6</sub> S
<b>Molecular Weight:</b>	747.73
<b>Target:</b>	JAK
<b>Pathway:</b>	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 83.3 mg/mL (111.40 mM)  
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		1.3374 mL	6.6869 mL	13.3738 mL
	5 mM		0.2675 mL	1.3374 mL	2.6748 mL
	10 mM		0.1337 mL	0.6687 mL	1.3374 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for JAK2 JH2 domain, with a K<sub>d</sub> of value 0.2 μM<sup>[1][2]</sup>.

#### In Vitro

JAK2 JH2 Tracer shows a minimum tracer concentration that retains a satisfactory signal-to-noise ratio is found to be 1.5 pM<sup>[1]</sup>.

?JAK2 JH2 Tracer shows a dissociation constants near 0.2 μM<sup>[1]</sup>.

?JAK2 JH2 Tracer shows a high binding affinity with a K<sub>d</sub> value of 0.2 μM for JAK2 JH2 domain by saturation experiments<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

The possibility that mutations within the JAK2 JH2 domain may be associated with pathology, which is associated with a hyperactive kinase and a hematopoietic malignancy phenotype in flies<sup>[2]</sup>.

?Specific mutation in the JAK2 JH2 domain is associated with several myeloproliferative diseases<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- 
- SLAS Discov. 2023 May 4;S2472-5552(23)00036-9.
  - Patent. US20220213108A1.
  - Patent. US20210395257A1.
  - Patent. US20210395251A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. *Curr Opin Genet Dev.* 2007 Feb;17(1):8-14.

[2]. Newton AS, et al. JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules. *ACS Med Chem Lett.* 2017 May 17;8(6):614-617.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA